证券代码：300194 证券简称：福安药业 公告编号：2025-035 福安药业（集团）股份有限公司 2025年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）2025 年半年度权益分 派方案已获 2025 年 9 月 15 日召开的 2025 年第一次临时股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、2025 年 9 月 15 日公司召开 2025 年第一次临时股东大会，审议通过了 《关于公司<2025 年中期现金分红方案>的议案》。公司 2025 年半年度利润分配 方案为：以公司现有总股本 1,189,712,382 股为基数，向全体股东每 10 股派发 现金股利 0.20 元人民币（含税），共计派发现金股利 23,794,247.64 元（含税）。 不送红股，不以资本公积金转增股本。 2、董事会审议利润分配预案后至实施前，公司股本如发生变动，将按照分 配总额不变的原则对分配比例进行调整。自分配方案披露至实施期间，公司股本 总额未发生变化 ...

Core Viewpoint - The company Fu'an Pharmaceutical (Group) Co., Ltd. has approved a cash dividend distribution plan for the first half of 2025 during a temporary shareholders' meeting held on September 15 [1] Group 1: Dividend Distribution Details - The total share capital is 1,189,712,382 shares, and the company will distribute a cash dividend of 0.2 yuan (including tax) for every 10 shares, totaling 23,794,247.64 yuan [1] - The record date for the dividend distribution is September 24, and the ex-dividend date is September 25 [1] - The distribution will be made to all registered shareholders, with the cash dividends for A-share shareholders being handled by China Securities Depository and Clearing Corporation Limited, Shenzhen branch, and the company will bear legal responsibilities for self-distribution [1]

证券日报网讯 9月15日晚间，福安药业发布公告称，公司于2025年9月15日召开职工大会，会议经民主 讨论、表决同意选举杨勇先生为公司第六届董事会职工代表董事。 （文章来源：证券日报） ...

证券代码：300194 证券简称：福安药业 公告编号：2025-032 福安药业（集团）股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1．本次股东大会无增加、变更、否决提案的情况； 2．本次股东大会不涉及变更以往股东大会已通过的决议； 3．本次股东大会对中小投资者的表决单独计票，中小投资者指单独或者合 计持有本公司 5%以上股份的股东以外的其他股东，且不包含持有公司股份的公 司董事、监事、高级管理人员； 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间：2025 年 9 月 15 日（星期四）下午 14:30 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 15 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深圳证 券交易所互联网系统投票的具体时间为2025年9月15日上午9:15至下午15:00 期间的任意时间。 3、现场会议召开地点：重庆市渝北区黄杨路 2 号公司会议室。 4、会议召开方式：采取 ...

上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 邮编：200336 Building 34, Hongqiao Guesthouse, 1591 Hongqiao Rd., Shanghai，p.c: 200336 电话：+86 21 68769686 Tel ：+86 21 68769686 传真：+86 21 68769686 Fax：+86 21 68769686 上海东方华银律师事务所 关于福安药业（集团）股份有限公司 2025 年第一次临时股东大会 之 法律意见书 致：福安药业（集团）股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受福安药业（集团）股份 有限公司（以下简称"公司"或"福安药业"）委托，就公司召开 2025 年第一 次临时股东大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简 称"《股东会规则》"）等法律、法规和其他规范性文件以及《福安药业（集团） 股份有限公司章程》（以下简称"《公司章程》"）的有关规定，就公司本次股 东大会的召集、召开程序、出席会议人员的资格、召集人的资格、表决程序和表 ...

截至本公告披露日，黄涛先生持有公司股份 8,786,688 股，不存在应当履行 而未履行的承诺事项。其副总经理职务原定任期至公司第六届董事会届满止，即 2027 年 11 月 19 日止。在原定副总经理职务任期及任期届满后六个月内仍将继 续遵守《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》、《深 圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减 持股份》等相关法律法规对任期届满前离任高级管理人员股份转让的规定。 证券代码：300194 证券简称：福安药业 公告编号：2025-034 福安药业（集团）股份有限公司 副总经理离任公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"） 董事会今日收到公司副 总经理黄涛先生的书面辞职报告，黄涛先生因工作调整原因，申请辞去公司副总 经理职务。黄涛先生离任公司副总经理职务后，仍将继续担任公司副董事长职务。 根据《公司法》、《公司章程》等相关规定，黄涛先生的辞职报告自送达公司 董事会之日起生效。其离任公司副总经理职务不会对公司正常生产 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-033 福安药业（集团）股份有限公司 关于董事离任暨选举职工代表董事的公告 福安药业（集团）股份有限公司（以下简称"公司"） 董事会近日收到公司董 事杨勇先生的书面辞职报告，杨勇先生因工作调整原因，申请辞去其所担任的公 司董事职务。杨勇先生离任公司股东代表董事后，仍将继续担任公司其他职务。 根据《公司法》《公司章程》等有关规定，杨勇先生离任公司董事不会导致 公司董事会成员人数低于法定人数，不会影响公司董事会的正常运行，亦不会对 公司的规范运作和日常运营产生不利影响，杨勇先生的辞职报告自送达公司董事 会之日起生效。 二、关于职工代表董事的选举情况说明 根据最新修订的《公司法》等法律法规和规范性文件及《公司章程》等相关 规定，公司于 2025 年 9 月 15 日召开职工大会，会议经民主讨论、表决同意选 举杨勇先生为公司第六届董事会职工代表董事（简历详见附件），任期自本次职 工大会审议通过之日起至第六届董事会任期届满为止，可连选连任。 上述职工代表董事符合《公司法》等法律法规和《公司章程》规定的任职条 件。董事会中兼任公司高级管理人员以及由职工代表担 ...

Group 1 - The core viewpoint of the article highlights that Fuan Pharmaceutical is actively responding to investor concerns regarding measures against internal competition in the pharmaceutical industry [2] - The company emphasizes that at the national level, procurement measures have been optimized to adhere to principles such as "stabilizing clinical practices, ensuring quality, preventing collusion, and combating internal competition" [2] - Fuan Pharmaceutical indicates that these efforts have led to a gradual normalization of industry order, reduced the burden of medication costs for the public, and improved the overall quality and accessibility of medications [2]

Core Insights - Fu'an Pharmaceutical experienced a stock decline of 1.30% on September 9, with a trading volume of 71.88 million yuan [1] - The company reported a financing buy-in of 12.32 million yuan and a net financing buy of 507,300 yuan on the same day [1] - As of September 9, the total financing and securities lending balance for Fu'an Pharmaceutical was 452 million yuan, representing 8.37% of its market capitalization [1] Financing Summary - On September 9, Fu'an Pharmaceutical had a financing buy-in of 12.32 million yuan, with a current financing balance of 452 million yuan, which is above the 90th percentile of the past year [1] - The securities lending data showed no shares were repaid or sold on September 9, with a remaining securities lending balance of 1,362 yuan, indicating a high level compared to the past year [1] Company Overview - Fu'an Pharmaceutical, established on February 25, 2004, and listed on March 22, 2011, is based in Chongqing and primarily engages in the research, production, and sales of antibiotic raw materials and formulations [1] - The company's revenue composition includes 56.60% from formulations, 39.44% from raw materials and intermediates, 3.55% from other sources, and 0.41% from drug distribution and others [1] Shareholder and Financial Performance - As of August 29, Fu'an Pharmaceutical had 40,900 shareholders, an increase of 1.67%, with an average of 23,695 circulating shares per person, a decrease of 1.64% [2] - For the first half of 2025, the company reported a revenue of 921 million yuan, a year-on-year decrease of 35.76%, and a net profit attributable to shareholders of 113 million yuan, down 47.74% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 666 million yuan in dividends, with 178 million yuan distributed over the past three years [2] - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 5.45 million shares, a decrease of 5.04 million shares from the previous period [2]

Overview - The market for Doxofylline tablets in China is steadily growing, driven by a large population of asthma patients, with sales expected to reach 125 million yuan in 2024, representing a year-on-year growth of 4.17% [1][8] - Public medical institutions account for over 90% of the sales, and the aging population is expected to further increase demand for Doxofylline tablets [1][8] Industry Chain - The upstream of the Doxofylline tablet industry includes raw materials, excipients, packaging materials, and pharmaceutical equipment; the midstream consists of production enterprises; and the downstream includes public medical institutions, physical pharmacies, e-commerce channels, and end consumers [4][5] Market Demand - The demand for Doxofylline tablets is significantly influenced by the procurement needs of public medical institutions, which are the primary sales channel due to the prescription nature of the drug [6] - As of the end of 2024, the number of medical institutions in China is projected to reach 1.092 million, a year-on-year increase of 2.0%, which will further expand the demand for Doxofylline tablets [6] Patient Demographics - The number of asthma patients in China is expected to reach 72.4 million in 2024, with a year-on-year growth of 4.32%, contributing to the increasing clinical demand for Doxofylline tablets [8] Competitive Landscape - The Doxofylline tablet market in China features both international companies and domestic firms, with local companies dominating the market. The competitive landscape is expected to evolve due to regulatory policies and procurement reforms [9][10] - Key domestic players include Fuan Pharmaceutical and Zhejiang Anglikang Pharmaceutical, with Fuan Pharmaceutical reporting a total revenue of 2.391 billion yuan and a gross profit margin of 52.96% in 2024 [10][11] Future Trends - The demand for Doxofylline tablets is anticipated to grow significantly in grassroots medical institutions as healthcare policies advance, leading to a downward trend in treatment accessibility [11] - Continuous implementation of volume-based procurement policies will encourage companies to enhance production efficiency and cost control, potentially increasing market concentration and optimizing the competitive landscape [11]